Danziger Asaf's Form 4 filing
NovoCure Ltd (NVCR) · filed Nov 29, 2021
- Accession no.
- 0001645113-21-000116
- Filed
- Nov 29, 2021
- Trade date
- Nov 26, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $509.5K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Danziger AsafCIK 0001654435 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2021 | Ordinary Shares | PPurchaseAcquired | +3,870 | $102.36F1 | +$396,133.2 | 12,172 | Direct | |
| Nov 26, 2021 | Ordinary Shares | PPurchaseAcquired | +1,000 | $103.37 | +$103,370 | 13,172 | Direct | |
| Nov 26, 2021 | Ordinary Shares | PPurchaseAcquired | +104 | $96.50 | +$10,036 | 13,276 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60. The price reported above reflects the weighted average purchase price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.